# A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT02367781** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 723 (actual)

## Conditions studied

- Carcinoma, Non-Squamous Non-Small Cell Lung

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- **DRUG:** Carboplatin
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02367781
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-16
- **Primary completion:** 2018-03-15
- **Final completion:** 2021-01-18
- **Target enrollment:** 723 (ACTUAL)
- **Last updated:** 2021-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367781, "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT02367781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*